Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

We evaluated the efficacy of carboplatin, irinotecan, and bevacizumab among bevacizumab-naïve, recurrent glioblastoma (GBM) patients in a phase 2, open-label, single arm trial. Forty eligible patients received carboplatin (area under the plasma curve [AUC] 4 mg/ml-min) on day one, while bevacizumab...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Reardon, David A., Desjardins, Annick, Peters, Katherine B., Gururangan, Sridharan, Sampson, John H., McLendon, Roger E., Herndon, James E., Bulusu, Anuradha, Threatt, Stevie, Friedman, Allan H., Vredenburgh, James J., Friedman, Henry S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2011
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3616617/
https://ncbi.nlm.nih.gov/pubmed/21986722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0722-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia